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Background: Circulating tumor cells (CTCs) are malignant cells that have migrated from solid cancers into the
blood, where they are typically present in rare numbers. There is great interest in using CTCs to monitor response
to therapies, to identify clinically actionable biomarkers, and to provide a non-invasive window on the molecular
state of a tumor. Here we characterize the performance of the AccuCyte® – CyteFinder® system, a comprehensive,
reproducible and highly sensitive platform for collecting, identifying and retrieving individual CTCs from microscopic
slides for molecular analysis after automated immunofluorescence staining for epithelial markers.
Methods: All experiments employed a density-based cell separation apparatus (AccuCyte) to separate nucleated
cells from the blood and transfer them to microscopic slides. After staining, the slides were imaged using a digital
scanning microscope (CyteFinder). Precisely counted model CTCs (mCTCs) from four cancer cell lines were spiked
into whole blood to determine recovery rates. Individual mCTCs were removed from slides using a single-cell
retrieval device (CytePicker™) for whole genome amplification and subsequent analysis by PCR and Sanger
sequencing, whole exome sequencing, or array-based comparative genomic hybridization. Clinical CTCs were
evaluated in blood samples from patients with different cancers in comparison with the CellSearch® system.
Results: AccuCyte – CyteFinder presented high-resolution images that allowed identification of mCTCs by
morphologic and phenotypic features. Spike-in mCTC recoveries were between 90 and 91%. More than 80% of
single-digit spike-in mCTCs were identified and even a single cell in 7.5 mL could be found. Analysis of single SKBR3
mCTCs identified presence of a known TP53 mutation by both PCR and whole exome sequencing, and confirmed
the reported karyotype of this cell line. Patient sample CTC counts matched or exceeded CellSearch CTC counts in
a small feasibility cohort.
Conclusion: The AccuCyte – CyteFinder system is a comprehensive and sensitive platform for identification and
characterization of CTCs that has been applied to the assessment of CTCs in cancer patient samples as well as the
isolation of single cells for genomic analysis. It thus enables accurate non-invasive monitoring of CTCs and evolving
cancer biology for personalized, molecularly-guided cancer treatment.* Correspondence: ekaldjian@rarecyte.com
†Equal contributors
1RareCyte, Inc, Seattle, WA, USA
Full list of author information is available at the end of the article
© 2015 Campton et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Campton et al. BMC Cancer  (2015) 15:360 Page 2 of 13Background
Cancer metastasis accounts for 90% of cancer deaths [1].
Circulating tumor cells (CTC) are malignant cells that
migrate from a cancer into the bloodstream; most CTCs
die, but some exit the circulation to develop into metas-
tases [2]. High numbers of CTC are associated with
shorter overall and progression free survival [3-5]. CTCs,
however, are rare – it is typical for one CTC to be
present for every million white blood cells or more – and
thus detecting and measuring CTC requires highly sensi-
tive technology.
Platforms for CTC identification have been developed
based on size, protein expression, or other physical char-
acteristics (reviewed in [6]). Currently, the only FDA-
cleared platform for CTC enumeration is the CellSearch®
system (Veridex, Raritan, NJ, USA), and is used for moni-
toring CTC in patients with colorectal, breast, and prostate
cancer. This system is based on automated immuno-
magnetic capture of EpCAM expressing cells, followed by
staining for DNA and cytokeratin to verify that captured
cells are nucleated and epithelial in origin. An exclusionary
stain for CD45 is included to prevent false positive identifi-
cation of white blood cells that may be non-specifically
captured. False negatives are an acknowledged weakness of
immuno-magnetic capture, which will not identify CTCs
that express low levels of the capture antigen. Other tech-
nologies for CTC analysis currently under development in-
clude other immunomagnetic positive or negative selection
methods, microfluidic chips, filters, isolation based on cell
deformability or cell density, and dielectrophoretic separ-
ation. Although there are advantages to each technology,
there are also limitations. Microfluidic chips and filters that
fractionate by size will not capture small CTCs. Most tech-
nologies do not provide high-resolution visualization of
cells. Often sensitive technologies are not specific, and vice
versa. Some require red blood cell lysis, which may damage
cells. Finally, the ability to robustly retrieve individually
identified cells within a practical workflow remains elusive.
The use of information from CTCs for therapeutic
decision-making is in its infancy. There is great interest
in exploiting CTCs as a window on the molecular state
of a tumor, since understanding the evolutionary path of
a cancer may predict resistance before overt clinical
progression, potentially allowing for the pre-emptive se-
lection of a more effective therapy. An ideal CTC ana-
lysis platform would provide unambiguous morphology
for definitive CTC identification, comprehensive CTC
enumeration for monitoring a patient’s response to ther-
apy, flexible characterization of biomarkers (including
drug targets), and also enable isolation of CTCs for mo-
lecular analyses.
We characterize here the performance of the Accu-
Cyte® – CyteFinder® system: a comprehensive, reprodu-
cible and highly sensitive dual-technology platform forcollecting, identifying and analyzing CTCs, that employs
two complementary technologies that surround a stain-
ing step using an automated immunohistochemistry in-
strument. The AccuCyte system – “front end” – is based
fundamentally on the density of CTCs, which is within
the range of the buffy coat. However, it is differentiated
from existing density-based methods that separate the
buffy coat from red blood cells and plasma by use of a
unique separation tube and collector device, which al-
lows virtually complete harvesting of the buffy coat into
a small volume for application to a microscopic slide with-
out cell lysis or wash steps, a potential source of CTC loss.
The CyteFinder system – “back end” – is an automated
scanning digital microscope and image analysis system
that presents high-resolution images of candidate cells
stained with well-characterized markers before definitive
classification as a CTC. CyteFinder includes an integrated
device (CytePicker™) for CTC retrieval that is mechanic-
ally precise and compatible with recently developed ad-
vanced genomic analysis methods for single CTCs.
Methods
Blood sample collection for spike-in experiments
Blood samples were collected from healthy volunteers at
Rainier Clinical Research Center according to a protocol
approved by Quorum Review institutional review board
(IRB, Seattle, WA, USA). Approximately 40 mL was col-
lected from healthy volunteers into anticoagulant EDTA
Vacutainer® tubes (Becton-Dickinson) with a proprietary
preservative (RareCyte, Seattle, WA, USA) and 20 mL
was collected from cancer patients into CellSave® tubes
(Veridex, Raritan, NJ, USA).
Tissue culture cells and model CTC (mCTC) spike-in
experiments
LNCaP and PC3 (Prostate), A549 (lung), and MCF7 and
SKBR3 (breast) cancer cell lines used as model CTCs
(mCTC) were all obtained from American Type Culture
Collection (ATCC, Manassas, VA, USA). LNCaP, PC3,
SKBR3, and A549 cell lines were maintained in RPMI 1650
medium and MCF7 cell lines were maintained in DMEM
medium. Media were supplemented with 10% FBS.
For percent recovery determination, nuclei or mito-
chondria of live mCTCs were fluorescently labeled with
Hoechst 33342 or Mitotracker Red (Life Technologies),
respectively, and drawn into a glass capillary tube (Vitro-
Tube, Mountain Lakes, NJ, USA). The cells within the
VitroTube were then scanned and counted using a
DeltaVision fluorescent microscope (GE, Issaquah, WA,
Additional file 1: Figure S1). Cells were expelled into
7.5 mL of blood by flushing the VitroTube with PBS and
then rescanning the tube for cells that were not expelled
to obtain the net precise count of the cells added to the
blood. On the order of 100 cells (range ~70 – 200) from
Figure 1 Components of the AccuCyte® system. From left to right
is pictured the float; the entire assembly for separation and isolation
of the buffy coat, including the Separation Tube with sealing ring;
the EpiCollector®; the Transfer Tube with septum base that that is
pierced by the EpiCollector needle to allow the flow of material
from the Separation Tube to the Transfer Tube; and the clamp that




Figure 2 Isolation of buffy coat and spreading onto microscopic
slides. (A) AccuCyte® Separation Tube and float after initial
centrifugation to separate 7.5 mL blood sample into its component
layers – plasma/buffy coat/red blood cells. (B) Isolated buffy coat in
Transfer Tube after transfer centrifugation. Arrow indicates the buffy
coat. (C) Addition of buffy coat mixture to slide. (D) Spreading cells
onto glass slide using CyteSpreader™ device.
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samples and then the sample was processed as described
in the next section.
For low mCTC detection experiments, freshly pre-
pared Hoechst 33342 labeled PC3 cells were suspended
at approximately 10,000 cells per mL and then pipetted
into a well of a multi-chambered glass slide that allowed
cells to remain in solution. The chambered slide was then
imaged on the CyteFinder® fluorescent microscope (Rare-
Cyte, described below). Individual PC3 cells were drawn
into a ceramic-tipped needle using the integrated Cyte-
Picker™ (RareCyte, described below) and deposited into a
PCR tube. The contents of the PCR tube were then
transferred into a blood sample by washing with PBS.
Alternatively, the contents of the CytePicker needle
were deposited into a separate sorting well on the cham-
bered slide. The sorting well was then imaged to deter-
mine an accurate count of the number of PC3 cells
deposited and the contents of the well were washed into a
blood sample with PBS. From 1 cell to 6 cells were spiked
into 7.5 ml blood samples.
Density enrichment and adherence of buffy coat to slides
Each spiked blood sample (7.5mls) was added to an
AccuCyte® Separation Tube (RareCyte) containing a
lozenge-shaped float (Figure 1). The float is a hollow
plastic cylinder with longitudinal ribs raised 75 microns
on the surface to prevent contact of the float body with
the inside wall of the tube, thereby providing channels
for fluid movement during centrifugation. The leading
and trailing ends of the float are rounded to reduce tur-
bulence and shear forces during centrifugation and so
prevent cell damage. The density of the float is adjusted
to allow it to rest at the red blood cell – plasma interface
(containing the buffy coat) after centrifugation, typically
between 1.051 and 1.057 gm/mL (or specific gravity units,
SG). Clinical samples were processed in the same way,
without the addition of spiked in cells. The sample was
centrifuged in a Beckman Allegra X-15R table top cen-
trifuge with SX4750 swinging bucket rotor (Beckman
Coulter, Indianapolis, IN) at 5250 relative centrifugal
force (RCF) for 30 minutes. Centrifuge adaptors spe-
cially made to contain these tubes and floats (RareCyte)
were used to allow a controlled expansion of the inner
diameter of the tube while preventing over-expansion or
rupture. Centrifugation separates the blood within the
Separation Tube into a bottom layer of packed red blood
cells (the hematocrit), a top layer of plasma, and the buffy
coat layer of white blood cells and platelets that collects
within space between the float and the wall of the tube
where it is easily visualized since its surface area expands
within the narrow space (see Figure 2).
After centrifugation the Separation Tube was removed
from the centrifuge adaptors and placed into a CyteSealer®(RareCyte), which applies a brass ring clamp (CyteSeal)
around the circumference of the tube at a position on the
float below the buffy coat layer, to create a barrier seal be-
tween the tube and the float. After the seal was applied,
the plasma was aspirated from the top of the float and ap-
proximately 4 ml of 1.793 gm/mL high-density retrieval
(HDR) fluid was added to the tube. A collection device
(EpiCollector®, RareCyte) was placed into the top of the
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that tapers to a 16 gauge needle oriented upwards. Excess
HDR fluid was expelled from the needle as the EpiCollec-
tor was inserted, eliminating dead space within the Epi-
Collector. A Transfer Tube pre-filled with approximately
250 uL of HDR fluid was placed into the EpiCollector; the
Transfer Tube has a rubber septum at its base that is
pierced by the needle within the EpiCollector. The Separ-
ation Tube with inserted EpiCollector and Transfer Tube
was centrifuged for 5 minutes at 500 RCF (Beckman
Allegra® X-15R) resulting in the buoyant displacement of
the buffy coat from the float into the Transfer Tube. The
workflow is summarized in Additional file 2: Figure S2.
Adherence Solution (1000 ul, RareCyte) was added to
the buffy coat in the collection tube and mixed. The sam-
ple was spread onto 8 SuperFrost® Plus slides (VWR) by
pipetting 150 uL of the mixture onto a slide resting in a
manual spreading device (CyteSpreader®, RareCyte) that
was designed to evenly distribute the sample in a mono-
layer across a defined region of the slide without making
contact with the slide and thus minimizing sample loss
(see Figure 2).
Immunofluorescence staining
Slides were dried for 30 minutes, fixed in 10% Neutral
buffered formalin (NBF, Sigma Aldrich) for 1 hour, washed
in PBS for 1 minute, and then incubated with 1 M Tris–
HCl 10 minutes to neutralize the NBF. Slides were washed
twice more with PBS and then stained using the Discovery
Ultra automated slide staining system (Ventana Medical
Systems, Tucson, Arizona, USA). Antigen retrieval was
performed by heating the slides for 8 minutes at 90°C
using buffer CC1. Slides were incubated with antibody to
EpCAM (SPM491, Spring Bioscience, Pleasanton, CA,
USA) diluted 1:100 for 32 minutes in a solution containing
2% goat serum and 2% BSA. Slides with A549 cells spiked
into blood were incubated with EGFR antibody (Invitro-
gen, clone 31G7) at 1:100 in place of EpCAM. Goat anti-
mouse secondary antibody conjugated to Alexa Fluor®647
(Life Technologies) was added at a 1:1000 dilution for
24 minutes in a 2% goat serum and 2% BSA solution. The
slides were then incubated with Alexa Fluor® 488 labeled
cytokeratin antibody (clones AE1 and AE3, 1:200 dilu-
tion, eBioscience, San Diego, CA, USA), Alexa Fluor®
488 labeled cytokeratin antibody (C11, 1:100 dilution,
BioLegend, San Diego, CA, USA), and R-phycoerythrin
(PE) labeled CD45 antibody (HI30, 1:100 dilution, Bio-
Legend) for 48 minutes in a 2% mouse serum and 2%
BSA solution. All antibodies and serum diluents were
stored in Inline User-Fillable Dispensers (Ventana) at 4x
working concentration and diluted into Reaction Buffer
(Ventana). DAPI or Hoechst 33342 was also included in
this last incubation at 5 ug/mL/mL. Washes were per-
formed by the Discovery Ultra as per manufacturer’sprotocol. After completion of staining slides were removed
and placed in Reaction Buffer for 5 minutes and washed 5
times with distilled water, and once with PBS. Coverslips
were applied using Fluoromount (Sigma Aldrich). Slides
were dried for at least 1 hour at room temperature before
scanning. For clinical samples, some slides were stained
with Ki67 antibody (clone 7B11, 1:100 dilution, Invitrogen,
Carlsbad, CA, USA ) using a similar protocol to that used
for EpCAM staining, substituting Ki-67 for EpCAM.
Clinical samples
Blood was collected from advanced breast, prostate and
colorectal patients being followed at the Seattle Cancer
Care Alliance according to a protocol approved by the
Fred Hutchinson Cancer Research Center IRB. Blood
was collected from a patient with triple-negative breast
cancer as part of the ITOMIC study by the Center for
Cancer Innovation at the University of Washington (clini-
caltrials.gov identifier NCT01957514); the study protocol
was approved by the Fred Hutchinson Cancer Research
Center IRB. Appropriate informed consent was received
from all cancer patients. Blood samples were processed
onto slides and stained on the Discovery Ultra as de-
scribed above.
Automated image capture and analysis
After staining, slides were placed onto the CyteFinder
digital scanning microscope to acquire fluorescent im-
ages. The microscope is oriented with the objective posi-
tioned below the sample. For each slide, the CyteFinder
acquired 4-channel fluorescent images of 2542 discrete
fields of view to cover the area on the slide where the
sample was spread (Additional file 3: Figure S3). Individ-
ual fields of view overlap by approximately 50 μm on all
sides to prevent obtaining partial images of cells on the
borders of adjacent fields. A solid-state, LED illuminator
(Lumencor, Beaverton, OR) was used to excite the fluoro-
phores. Images were captured using a Coolsnap® EZ CCD
camera (Photometrics, Tucson, AZ). Filters for excitation
and emission were from the Brightline® product collection
(Semrock, Rochester, NY). Low magnification scan images
were acquired with a Nikon 10X 0.3NA objective (Nikon
Instruments, Melville, NY) with a lateral resolution of
1.06 um. The high resolution images of revisited points
were acquired with a Nikon 40X 0.6NA objective with a
lateral resolution of 529 nm. Revisited points were imaged
with a “stack” of images through the Z plane with 1um
steps. The images were presented to the reviewer as indi-
vidual z planes rather than projection images.
Images were analyzed for the presence of signal above
background for each channel (except nuclear dye chan-
nel) using Analyzer image analysis software (RareCyte)
that employs an adaptive auto-threshold algorithm. The
primary detection was performed on the fluorescent
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The objects identified by their CK signal were then ana-
lyzed to determine their correlation with the CD45 label (a
negative marker). Highly correlative objects were rejected
as this indicated the presence of CD45 label on CK positive
objects. Objects that are determined by the algorithm to be
CK positive and CD45 negative were presented to the
reviewer for classification (see next section). Objects to
be classified are termed “glyphs” and are highlighted by
a 200 × 200 pixel box.
Review and cell classification
CyteMapper® is a review software system that presents
glyphs to the reviewer as a row of 4 boxes showing each
individual fluorescence channel as grayscale images with
scalable brightness and contrast (Additional file 4:
Figure S4). A later version of the viewer included a fifth
box showing a color composite image of channels super-
imposed on one another. The reviewer can view the entire
panel in which the glyph was found to determine its rela-
tionship to other cells in the sample and can zoom in on
images to facilitate classification.
Objects were classified into three categories: (1) “Cell”,
(2) “Not a Cell”, or (3) “Indeterminate” based on estab-
lished criteria for cells of epithelial origin [7-9]. A “Cell”
met all criteria for a CTC, including positive nuclear
stain, a positive cytokeratin signal, and a negative CD45
signal. EpCAM or EGFR (for A549 mCTCs) were used
as additional interpretive markers for classification of
“Cell”. An “Indeterminate” object met a combination of
criteria that may include positive signal in two of three
channels and/or positive signal in the “negative” channel.
“Not a Cell” is used for all other objects. A tally of the
number of objects in each category was kept by the soft-
ware and reported upon saving the reviewed file. Only ob-
jects classified as “Cell” were included in tallies of CTCs.
The performance of CyteMapper review for the mCTC
spike-in experiments was shared among three scientists
with extensive experience in the investigation of CTCs
and in the use of CyteMapper for the identification of
epithelial cells.
CTC enumeration comparison
Blood from 10 patients with advanced breast, prostate or
colorectal cancer was evaluated in a clinical feasibility
study. Two 7.5 mL specimens of blood were drawn from
cancer patients at the same time; one was given to the
University of Washington (UW) Medical Center clinical
laboratory for CTC evaluation by CellSearch and the
other to RareCyte for CTC evaluation by AccuCyte –
CyteFinder. CTCs were counted by CellSearch accord-
ing to manufacturer’s instructions (Janssen Diagnostics,
Raritan, NJ) and by AccuCyte – CyteFinder as described
above. CTCs identified by AccuCyte – CyteFinder metCellSearch criteria: positive staining for cytokeratin and
nucleus and negative staining for CD45. Investigators at
RareCyte were blinded to the CellSearch counts until
after the results from both assays were documented and
delivered to investigators at UW.
Retrieval of individual mCTC from slides
Isolation of single cells from slides was performed with
CytePicker that is integrated with CyteFinder (Additional
file 5: Figure S5). CytePicker is a hydraulically controlled
semi-automated single cell retrieval device that contains
three critical parts: (1) needle with 22 um-bore ceramic
tip, (2) pump capable of 200 pL droplet resolution, (3)
precision Z-positioning system using a piezo-electric ac-
tuator. Imaging of the cells was performed with a 10x,
0.30NA objective through the slide (rather than through
a coverslip) so that uncovered cells are accessible to the
ceramic tipped needle above the slide. Chromatic aberra-
tions are measured and compensated for in software
prior to imaging so that all fluorescent channel images
are appropriately co-registered.
SKBR3 mCTCs were spiked into blood, which was
processed and stained as above for cytokeratin, EpCAM,
CD45 and nuclear DNA. Samples that were used for in-
dividual cell retrieval were prepared without a coverslip.
After CyteFinder scanning, the Imager3 software module
used the data generated from the scan/analysis/review
routine to create a list of coordinates of cellular locations
on the slide. Individual cell locations were visited (and
viewed at 40× objective magnification if desired) to verify
that the candidate cell met CTC criteria described above.
A droplet of PBS was deposited on the slide in the area of
the cell of interest. Using the CytePicker software module,
the needle was lowered to make contact with the sample
surface. Using the piezo-actuated Z control, the operator
directed the needle tip 20–30 μm past the surface of the
sample to “cut” into the sample layer. A controlled circu-
lar movement (termed “wiggle”) with a diameter between
25 and 40 μm was directed by the Imager3 software to
dislodge the cell from the surface of the slide into the nee-
dle tip. Removal of the cell was confirmed visually (see
Additional file 6: Figure S6). The needle was then raised
and the operator placed a PCR tube under the needle. A
volume of 2 μL was then dispensed into the bottom of the
PCR tube and the sample was immediately frozen at -80C.
Laboratory workflow
The workflow for the process of CTC collection, slide
preparation and staining, scanning and image analysis
and individual cell retrieval involves automated and
manual steps. The times required for each step, and the
proportion of “hands-on” time for the process that was
current at the time of the submission of the revised
manuscript is listed in Table 1. The total laboratory time






Image Review/CTC Confirmation 15/15
Total AccuCyte - CyteFinder 400/55
CytePicker cell retrieval (per cell) 2 - 3
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hands-on time of about 1 hour. Additional samples may
be batch processed in the AccuCyte and automated
staining steps with minimal additional hands-on time.
Whole genome amplification and molecular analysis
of mCTC
After thawing individually picked SKBR3 cells at room
temperature, the cells were lysed and genomes amplified
with the Ampli1 WGA procedure according to manufac-
turer’s instructions (Silicon BioSystems, Bologna, Italy).
Approximately 1 μL of the WGA reaction product was
used for amplification of the TP53 gene that encodes the
region of the protein containing the p.R175H mutation.
Nested PCR primers were designed from the NCBI hu-
man reference genomic sequence and amplified from
ch17:7577987–7578592 for the outer primers (5′-CC
CTGACTTTCAACTCTGTCTC-3′ and 5′-AGGCCCT
TAGCCTCTGTAA-3′) and ch17:7578281–7578503 for
the inner primers (5′-GTGCAGCTGTGGGTTGATT-3′
and 5′-GGGCCAGACCTAAGAGCAAT-3′) using Pri-
mer3 software [10,11]. The amplicon generated from the
outer primer set was 606 bp and from the inner primer
set was 224 bp. Approximately 1 μL of sample from the
WGA product was transferred into a PCR tube with 2X
PCR reaction mix (New England Biolabs, Ipswich, MA,
USA), 0.5 μM of each primer, and water was mixed and
placed into a thermal cycler (Thermo Fisher Scientific).
Thermal cycling conditions were as follows: (1) incubation
at 94°C for 7 minutes, (2) 30 cycles of 94°C for 30 seconds,
60°C for 30 seconds and 72°C for 30 seconds, (3) final ex-
tension at 72°C for 7 minutes. Samples were held at 4°C
until they were analyzed by gel electrophoresis. After
PCR, the presence of the 224 bp amplicon was confirmed
by loading a portion of the reaction onto a 2% agarose gel,
and staining with SYBR® safe (Invitrogen) and comparing
its migration to a DNA size standard.
The resulting amplicon was purified from primers using
the DNA Clean & Concentrator (Zymo Research, Irvine,
CA, USA) according to manufacturer’s instructions. Ap-
proximately 1 ng of amplicon was mixed with sequencing
primer (inner PCR primers) and BigDye® Terminator se-
quencing reactions (Life Technologies) were performedaccording to manufacturer’s directions. Reactions were
run on a 3730XL DNA Analyzer (ThermoFisher Scien-
tific). Sequences were analyzed for the presence of the
nucleotide mutation that defines p.R175H (c.524G > A).
Array CGH
WGA products from single SKBR3 cells were analyzed
by array CGH using oligonucleotide-based SurePrint
G3 Human CGH 4x180K arrays from Agilent Tech-
nologies (Santa Clara, CA) as described previously [12].
Briefly, one microgram of WGA DNA was labeled per
hybridization. Since the WGA products ranged in size
from 100 bp to 1 kb, it was not necessary to perform
DNA fragmentation before labeling. Test DNAs were
labeled with dCTP-Cy5 and reference DNAs were labeled
with dCTP-Cy3, for 2 hours at 37°C using a Spectral La-
beling Kit (Perkin Elmer, Boston, MA). Unincorporated
nucleotides were removed using a MultiScreen-PCRμ96
Filter Plate (Millipore, Billerica, MA). Hybridizations
were carried out at 65°C for 40–72 hours to enhance
the binding of WGA DNA, after which they were
washed and scanned using an Agilent Microarray Scan-
ner (PN G2565BA). Data was extracted using Agilent’s
Feature Extraction software (version 9.5.3.1) and was ana-
lyzed using Agilent CytoGenomics Edition 2.5.8.11. The
DNA used as a reference for each single lymphoblast cell
WGA product was a pool of WGA DNA from multiple
(5–10 single cell) WGA reactions from either male or fe-
male lymphoblast reference cell lines. Gender-mismatched
references were used unless otherwise indicated.
Slides were scanned into image files using the Agilent
G2565 Microarray Scanner. Scanned images were quanti-
fied using Agilent Feature Extraction software (v10.10.0.23).
Text file outputs containing quantitative data were
imported into the Agilent CytoGenomics software (ver-
sion 2.5.8.11). Data were analyzed using the Aberration
Detection Method 2 (ADM2) statistical algorithm at a
threshold of 6.0 to identify genomic intervals with copy
number changes. To reduce false positive calls, a filter
was applied to define the minimum log2 ratio (0.25), the
minimum size (100 kb) and the minimum number of
probes (100) in a CNV interval. The Derivative Log Ratio
Spread (DRLS), a measure of probe to probe noise calcu-
lated by the CytoGenomics software, was used as a per-
formance measure for hybridization quality.
The karyotype of SKBR3 for reference comparison is found
at this this website: http://old-www.path.cam.ac.uk/~pawefish/
BreastCellLineDescriptions/sk-br-3.htm.
Whole exome sequencing
A DNA fragment library was constructed from WGA
products from individual SKBR3 cells picked from whole
blood spike-in samples using a modified version of the
NEBNext (New England Biolabs) protocol. Libraries were
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(Roche NimbleGen) for the coding portion of the genome.
The target includes all coding content from the CCDS,
RefSeq and miRBase databases. Paired-end (100 base pair)
sequencing of enriched libraries was performed using a
HiSeq 2500 system with TruSeq v3 chemistry (Illumina)
with a read depth of 15 – 30x. The resulting reads were
aligned to the genome human reference (hg19) using
BWA (Burrows-Wheeler Aligner) [13] and variants called
with GATK (Genome Analysis Toolkit) [14,15].
Results
Recovery of spiked-in mCTC from whole blood
Four cancer cell lines representing breast, prostate and
lung cancer were used for mCTC recovery experiments.
Approximately one hundred tumor cells (range 70 – 210)
were precisely counted in capillary tubes and then spiked
into 7.5 mL of whole blood. After cells were spiked into
blood, the sample was centrifuged in the AccuCyte Separ-
ation Tube resulting in separation of the blood into its
component layers – plasma, buffy coat and red blood cells
(Figure 2A). The buffy coat was collected as described in
Methods by centrifugation into the Eppendorf Transfer
Tube (Figure 2B). Cells collected in the Transfer Tube
were spread onto a glass slide with the CyteSpreader
(Figure 2 C and D), and stained on the Discovery Ultra
automated staining system, using antibodies to the epi-
thelial antigens cytokeratin and EpCAM (EGFR in the
case of A549), the leukocyte antigen CD45, and a DNA
dye (Hoechst 33342 or DAPI). Epithelial staining of the
mCTC distinguished them from cells normally within
the blood (Figure 3). Slides were imaged on CyteFinder.
After scanning, the images were analyzed by CyteMap-
per software, designed to identify cells by user-defined
criteria including signal intensity, object size and cellu-
lar morphology. A blinded reviewer, different from the
person who performed the spike-in, reviewed candidate
cells by examining for positive epithelial antigen staining,A B
Figure 3 Fluorescently stained model circulating tumor cells
collected and imaged using the AccuCyte® – CyteFinder® system.
(A) A549 mCTC stained with antibody to EGFR (red), cytokeratin
(green), and nuclear dye (blue). (B) Cluster of LnCAP mCTCs stained
with antibody to EpCAM (red), cytokeratin (green), and nuclear dye
(blue). Cells imaged at scanning 10X objective magnification.presence of a nucleus, morphology consistent with a
tumor cell, and absence of staining for CD45. Cells that
met these criteria were counted as mCTC. Objects could
be viewed in greater detail within the software if desired.
Representative images of A549 and LNCaP mCTC are
shown in Figure 3.
Tumor cell recovery counts were compared to the
number of cells spiked into the blood in five replicates
of each cell line. The mean recovery of mCTC detected
by the AccuCyte – CyteFinder system ranged from 90% to
91% with an average recovery of 90.5% and standard devi-
ation of 4.5 (Figure 4A). The mean percent recovery was
90.5 +/− 4.7 for A549, 90.0 +/− 2.6 for LNCaP, 90.2 +/−
3.7 for PC3, and 91.3 +/−7.1 for MCF7. The consistent re-
covery and narrow distribution indicates that the cell
counts are highly reproducible over multiple samples
and across cell lines of known high (LNCaP, MCF7) or
low (PC3, A549) EpCAM expression. Linear regression
analysis of the number of identified tumor cells against
the number of spiked-in tumor cells produced a slope
of 0.9588 and an intercept of 5.802 across all lines
(Figure 4B). The correlation analysis of the results from
all cell lines yielded an R2 value of 0.9826. There was noFigure 4 Recovery of known number of cells spiked into blood.
(A) Scatter dot plot of spike-in cells with mean represented by the
horizontal lines and standard deviation represented by vertical lines.
(B) Linear regression analysis of recovered cells versus spiked in cells.
Table 2 Recovery of single-digit spike-in mCTCs
Experiment A B C D E F G H I J
Number spiked-in mCTCs 1 1 1 2 2 3 3 3 5 6
Number mCTCs identified 1 1 0 2 2 3* 3 2 4 4
*In experiment F two additional cytokeratin-positive cells were identified by
initial evaluator; these were determined on expert review to have morphology
inconsistent with characterization as CTCs but consistent with being squamous
cell contaminants from venipucture.
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range of cells spiked into the blood samples.Detection of single-digit numbers of spiked-in mCTC
Individually collected PC3 cells were spiked into 7.5 mL
of whole blood using the CytePicker (see Methods) to
determine the sensitivity of the AccuCyte – CyteFinder
system to detect very low numbers of mCTC. Blood
from 10 samples spiked with between 1 and 6 PC3 cells
was processed to slides, stained and analyzed as de-
scribed for the recovery experiments. The reviewer was
blinded to the number of cells spiked-in. In 6 samples
all cells were identified. In 3 samples, N – 1 cells were
identified, and in 1 sample, N – 2 cells were identified,
where N is the number of cells spiked in (Table 2). In
total, 22 out of 27 (81%) mCTCs were identified, and in
two of three experiments in which a single cell was spiked
in, that one cell was identified. In one sample that had 3Figure 5 CTCs from a triple negative breast cancer patient. Blood was pro
CyteMapper® software representative cells were re-imaged at 40X using the
patient stained with antibodies to cytokeratin (green), Ki67 (red) and DAPI
(B) Same CTC shown in A, but with only Ki67 antibody staining in red. (C, D)
(green) expression. DAPI was used to stain nuclei.mCTCs spiked in, 5 cells were identified. Upon review of
the cells by a board-certified anatomic pathologist, two of
the cells were determined to lack morphologic features of
the mCTCs but did have features of squamous cells, con-
sistent with venipuncture contaminants from skin. These
results indicate that the AccuCyte – CyteFinder system is
highly sensitive in identifying mCTCs at very low cell
numbers and is capable of detection of a single cell in
7.5 mL of blood and underscore the value of high-
resolution imaging for CTC classification.CTC detection and characterization in breast cancer
We applied the AccuCyte – CyteFinder system to the
analysis of CTCs in breast cancer. Figure 5 shows cells
from a patient with triple-negative breast cancer, having
the characteristic cytoplasmic cytokeratin (5 A,D) and
surface EpCAM (5C) staining and morphology of CTCs.
We observed CTCs attached to one another in clusters
(Figure 5C,D), which have been reported to be associated
with worse outcome [16,17]. Examination of cell physi-
ology markers in CTCs may be useful in investigation of
therapeutic response. Cells that proliferate despite expos-
ure to anti-cancer therapy by definition are not respond-
ing to the therapy, and thus may represent an important
subset of cells for investigation. Since the AccuCyte –
CyteFinder system is an open platform, we substituted an
antibody against the proliferation antigen Ki-67 for thecessed and scanned as described and after identification with the
CyteFinder® Scanner. (A) CTC from a triple negative breast cancer
(blue). Cell appears bi-nucleate, or may be near the end of cell division.
Cluster of many CTCs with heterogeneous EpCAM (red) and cytokeratin
Figure 6 Comparison of CTC counts between AccuCyte – CyteFinder and CellSearch. 10 paired blood samples from patients with advanced
prostate, breast or colorectal (CRC) cancer were processed independently using AccuCyte – CyteFinder or CellSearch systems to identify CTCs. In
3 samples counts equivalent (samples 1,3 and 4), in 3 samples AccuCyte – CyteFinder identified appreciably more CTCs than CellSearch (samples
2, 5 and 9), and in the remaining 4 samples numbers were very low by each method (3 CTCs or less).
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was seen in cells identified as CTCs by cytokeratin
staining (Figure 5A and B).
AccuCyte-CyteFinder comparison to CellSearch
Paired blood samples from a feasibility cohort of 10
patients with advanced breast, prostate or colorectal
cancer were evaluated by both AccuCyte-CyteFinder
and CellSearch CTC methods using similar criteria for
identification of CTCs. Investigators at RareCyte were
blinded to the CellSearch counts until after the results
from both assays were documented. CTC counts fellA B
Figure 7 Single cell mutation detection after whole genome amplification
mutations in the TP53 gene. Shown above is the region of the gene conta
cells spiked into blood, picked and amplified. CGC encodes the wild-type arg
nucleotides encoding these amino acids are underlined in the traces pictured
SKBR3 cells, (C) Mixture of mutant and wild type sequence most likely due tointo three categories: (1) equivalent, (2) very low by
both methods, or (3) notably higher with AccuCyte –
CyteFinder than CellSearch (Figure 6). These results are
consistent with findings in model CTCs spiked into
blood that yield equivalent numbers in cell lines that
express high EpCAM levels, but higher AccuCyte –
CyteFinder counts in lines that express low or absent
EpCAM (data not shown). A rational explanation is that
not all CTCs have sufficient EpCAM expression to be
collected by immunomagnetic bead capture, but have
adequate cytokeratin expression for identification of
epithelial origin.C
. Sanger sequencing traces from SKBR3 cells show single nucleotide
ining the p.R175H mutation from PCR products derived from single
inine and CAC encodes the mutant histidine found in SKBR3 cells. The
above. (A) Wild type sequence from a WBC, (B) Mutant sequence from
a contaminating WBC picked along with a SKBR3 cell.
Figure 8 Whole exome sequencing of SKBR3 mCTCs. The
chromosomal region containing the p.R175H mutation in TP53 is
shown from whole genome amplification products from 8 individual
cells and a pool of 5 cells that were picked from a slide processed
as described. The nucleotides in red represent the mutation; wild
type sequence is listed at the bottom. The mutation was identified
in all samples.
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To investigate whether genomic analyses can be per-
formed on individual CTC that have been identified and
retrieved using the methods described above, SKBR3
cells were spiked into a blood sample that was processed
using the AccuCyte – CyteFinder system. mCTCs were
identified and individually picked with the CytePicker
(see Methods). These cells were then subjected to whole
genome amplification (WGA). Using the WGA product,
a region of the TP53 gene known to contain an R175H
mutation in SKBR3 was amplified by PCR and the nucleo-
tide sequence of this region was determined by Sanger se-
quencing. CGC encodes the arginine found in the wild
type TP53 sequence and CAC encodes histidine, found in
the mutant variant. Sequence from a picked WBC from
the same blood sample the SKBR3 cells were spiked into
revealed wild-type TP53 (Figure 7A). The mutation was
clearly identified in SKBR3 (Figure 7B). Since SKBR3
cells are homozygous for this mutation, the sequence in
Figure 7B verifies that a SKBR3 cell was picked from
this slide independently. In Figure 7C the mutation was
observed in the background of the wild type TP53 se-
quence; this likely indicates presence of an adjacent
white blood cell in the WGA reaction.
Whole exome sequencing and array CGH of SKBR3 mCTC
A set of 9 SKBR3 WGA products from 8 individually
picked mCTCs and a pool of 5 picked mCTCs from a
spike-in blood sample were prepared for whole exome
sequencing. Despite low read depth (15 – 30×) the TP53
R175H mutation was clearly demonstrated to be present
in all 9 samples (Figure 8).
In a separate experiment, the WGA product from a sin-
gle SKBR3 mCTC picked from a spike-in blood sample was
used for array-based comparative genomic hybridization
(aCGH) using a reference male control DNA. The resulting
karyotype was consistent with the published karyotype of
this cell line (Figure 9). In addition to the expected sex
chromosome mismatch, some of the expected findings
that are consistent with these array results were: duplica-
tion of the majority of chromosome 7, 8q, proximal 10q,
and chromosome 20; deletion of 8p, distal 10q, 16q,
chromosome 18 (partial), and 19p. Findings that are not
in the published karyotype were: deletion of 2q, chromo-
some 4, and the majority of 5q, which could have been ac-
quired during culture.
Discussion
Here we have presented a dual-technology platform for
the identification and characterization of CTCs that is
comprehensive, reproducible, and sensitive. Across 4 dif-
ferent cancer cell lines, more than 90% of mCTCs spiked
into blood were consistently recovered in replicate experi-








Figure 9 Array CGH of a single SKBR3 mCTC. Whole genome amplification product from a single picked SKBR3 mCTC was compared to a male
control DNA sample by array-based hybridization. The horizontal axis shows chromosomal location. The vertical axis shows gains (above line) and
losses (below line) for regions of each chromosome. Red lines above and below the graphed data designate regions of amplification or deletion.
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mCTCs with minimal loss and an experimental limit of
detection of a single cell in 7.5 mL of blood. CTC counts
in advanced stage cancer patients either exceeded or were
similar to CellSearch CTC counts. Finally, individually vi-
sualized mCTCs were isolated using a retrieval device for
the performance of molecular genetic analyses – including
Sanger sequencing, whole exome sequencing, and array-
based comparative genomic hybridization – that employed
preparative single-cell whole genome amplification.
Our mCTC recovery experiments suggest that the frac-
tion of the buffy coat that is collected using the AccuCyte
system approaches 100%, since there is likely some de-
crease in CTC yield due to the staining and image analysis
steps. In contrast, CPT tube and Ficoll-Hypaque® density-
based separation methods are reported to have a max-
imum white blood cell yield of 60 – 80% and can be highly
variable [18,19]. Thus, this platform ensures that virtually
all of the CTCs present within a blood sample are depos-
ited onto slides for microscopic analysis, regardless of
their size or the expression of specific surface molecules.
In our experience, cytokeratin is a more reliable
epithelial marker than EpCAM, which has variable ex-
pression across cell lines and even within clinical CTCs
in a single cluster. Low EpCAM expression or EpCAM
downregulation in CTCs have been cited as reasons for
the inefficiency of EpCAM capture methods in certain
cancer types [20-22]. In our study, the PC3 cell line ex-
pressing very low levels of EpCAM was recovered from
spike in experiments as efficiently as cell lines expressing
higher EpCAM levels. CyteFinder incorporates high-
resolution (40× objective) cell imaging as an important
tool for definitively classifying CTCs. For the low number
spike-in experiments this tool was used to exclude
cytokeratin-positive cells that lacked mCTC morphology.
At the center of the platform workflow is a staining step
employing an automated IHC instrument (the Ventana
Discovery® Ultra). Automated IHC instruments are common
in histopathology laboratories worldwide, and their use sim-
plifies workflow and reduces hands-on time requirements
for sample processing. Moreover, they allow the application
of various antibody reagents, providing for an “open”platform for CTC evaluation. These reagents may be to
identify drug targets, such as Her2 for breast cancer, or non-
epithelial phenotypic markers, such as CD146 and NG2 for
melanoma, (data not shown) or physiologically meaningful
biomarkers, such as Ki67, as demonstrated above. Markers
for mesenchymal transformation or cancer differentiation
are equally possible to incorporate. Recently we have
demonstrated that CTC identification by the AccuCyte –
CyteFinder system is independent of automated staining in-
strument; spike-in recovery of PC3 cells on the Dako Auto-
stainer® Link 48 averaged 93%, and single digit spike-in limit
of detection was also one cell in 7.5 mL (data not shown).
In a clinical feasibility cohort of advanced breast, pros-
tate and colorectal cancer patients, AccuCyte – CyteFin-
der enumeration of CTCs compared favorably to the only
FDA-cleared system for counting CTCs (CellSearch). This
is consistent with the understanding that not all CTCs ex-
press sufficient EpCAM to be collected by immunomag-
netic bead capture. Clinical application of the AccuCyte –
CyteFinder system was also demonstrated in an evaluation
of CTCs in a patient with advanced triple-negative breast
cancer; here we demonstrated application of biomarkers
for proliferation (Ki-67) and drug targeting (Her2), and
observed cell clusters, which have been reported to be in-
dicative of aggressive disease [16,17].
False positive CTC identification by AccuCyte – Cyte-
Finder appears to be very low. In the spike-in recovery
study of 20 samples, recovery rate was never greater
than 100% (unlike some other CTC platforms), and in
the single-digit spike-in experiments, only one sample
had a higher CTC count than spike-in number, and these
cells could be morphologically distinguished as non-
malignant. Furthermore, in the ongoing comparison with
CellSearch, we have evaluated numerous samples in which
no cells have been found (data not shown). This is circum-
stantial evidence that false-positive identification is likely
to be extremely rare. Formal studies of false-positive rate
are important and will be performed in the future.
CTCs are increasingly regarded as windows through
which to observe dynamic changes in the molecular
biology of solid tumors. Retrieval of CTCs for molecular
analysis will thus likely be an important aspect of future
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integrated single cell retrieval device, the CytePicker, that
can routinely collect individual cells that are adherent to
microscopic slides after identification with CyteFinder. The
process is compatible with whole genome amplification of
single cells, which then can be followed by various molecu-
lar genetic analysis methods. Here we have shown that
both nested PCR followed by Sanger sequencing and whole
exome sequencing identifed a known TP53 mutation in
SKBR3 mCTCs, and that array-based comparative genomic
hybridization confirmed the reported SKBR3 karyotype.
Similar investigations are currently being undertaken in
single CTCs from cancer patient samples.
Conclusion
We have developed a comprehensive and sensitive
dual-technology platform for flexible identification and
characterization of CTCs on microscopic slides using
established histopathology staining instruments. The
platform has been successfully applied to longitudinal
investigation of a patient with breast cancer on a clinical
trial protocol and it can readily isolate single cells for se-
quencing and other genomic analyses. It thus permits
the non-invasive and repeated accurate monitoring of
therapeutic response and evolving cancer biology to en-
able personalized, molecularly-guided cancer treatment.
Additional files
Additional file 1: Figure S1. Live cells were freshly prepared as a
suspension and the nuclei were fluorescently pre-labeled before being
drawn into a capillary tube (VitroTube®). The VitroTube was then scanned
and cells were counted on a fluorescent microscope. Cells were expelled
into blood sample by flushing with PBS and the VitroTube was rescanned
and counted to obtain the net count of the cells added to the blood.
(A) Fluorescent scan of Hoechst-stained cells in VitroTube (transmitted
light overlay). (B) VitroTube on slide for scanning.
Additional file 2: Figure S2. Workflow for obtaining buffy coat using
the AccuCyte® density-based separation system. A Add blood into
AccuCyte Separation Tube containing float. B Centrifuge sample to
separate constituent layers (top to bottom: plasma, buffy coat, red blood
cells). C Apply sealing ring (arrow-head). D. Aspirate plasma (left); add
high-density retrieval (HDR) fluid (right). E Insert EpiCollector™. F. Insert
Transfer Tube pre-loaded with HDR fluid into EpiCollector. G. During
second centrifugation, the HDR fluid displaces buffy coat cells which float
to the top of the HDR fluid inside the Transfer Tube. H. Remove Transfer
Tube containing buffy coat (Note: small amount of residual plasma
remaining on float is collected, as well as small amount of red blood cells,
due to placement of the sealing ring just below buffy coat – red blood
cell interface).
Additional file 3: Figure S3. (A). Buffy coat spread onto slide prepared
for automated staining. (B) Scan of slide after immunofluoresence
staining comprised of 2419 individual 10x image panels. (C) The single
panel (arrow in panel B) shows one such 10x image identified by the
CyteMapper® software as containing a candidate CTC in box. (D) Cytokeratin
positive CTC. Stains: DAPI (blue), CD45 (orange) and cytokeratin (green).
Additional file 4: Figure S4. CyteMapper® review software display of
objects of interest from whole-slide scans. Candidate CTCs are identified
by the analysis software using criteria such as signal intensity, object size
and cellular morphology. Images are presented for characterization andenumeration of CTCs. Each channel can be viewed independently or in
any combination and objects can be shown in greater detail to resolve
subcellular details. The top row represents a fluorescent object found by
the software that was rejected by the reviewer since morphology and
staining are not consistent with classification CTC. The bottom row
represents a candidate cell classified as a mCTC that is positive in all
channels except for the channel containing CD45.
Additional file 5: Figure S5. CytePicker® single cell retrieval device.
Candidate CTCs that are identified after CyteFinder® imaging can be
picked using a software module that positions the needle tip over the
cell of interest.
Additional file 6: Figure S6. Visual confirmation of cell removal with
the CytePicker®. (A) 10X objective magnification image from CyteFinder
of a model CTC (PC3 cell) stained with anti-cytokeratin antibody (green)
in a background of white blood cells (blue nuclei) immediately before
picking using the CytePicker module. (B) Image of the same region of
the slide immediately after picking the model CTC. [Note: these images
were made using the most recent version of the CyteFinder with
CytePicker module].
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